Transperineal vs transrectal magnetic resonance and ultrasound image fusion prostate biopsy: a pair-matched comparison

• Published in: Scientific reports Vol. 13; no. 1; p. 13457
• Main Authors: Kaneko, Masatomo, Medina, Luis G., Lenon, Maria Sarah L., Hemal, Sij, Sayegh, Aref S., Jadvar, Donya S., Ramacciotti, Lorenzo Storino, Paralkar, Divyangi, Cacciamani, Giovanni E., Lebastchi, Amir H., Salhia, Bodour, Aron, Manju, Hopstone, Michelle, Duddalwar, Vinay, Palmer, Suzanne L., Gill, Inderbir S., Abreu, Andre Luis
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 18-08-2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/67; 692/308; 692/4025; 692/4028; 692/699; Biopsy; Humanities and Social Sciences; Lesions; Magnetic resonance imaging; multidisciplinary; Prostate cancer; Science; Science (multidisciplinary); Statistical analysis; Ultrasonic imaging; Ultrasound
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-40371-7

The objective of this study was to compare transperineal (TP) versus transrectal (TR) magnetic resonance imaging (MRI) and transrectal ultrasound (TRUS) fusion prostate biopsy (PBx). Consecutive men who underwent prostate MRI followed by a systematic biopsy. Additional target biopsies were performed from Prostate Imaging Reporting & Data System (PIRADS) 3–5 lesions. Men who underwent TP PBx were matched 1:2 with a synchronous cohort undergoing TR PBx by PSA, Prostate volume (PV) and PIRADS score. Endpoint of the study was the detection of clinically significant prostate cancer (CSPCa; Grade Group ≥ 2). Univariate and multivariable analyses were performed. Results were considered statistically significant if p < 0.05. Overall, 504 patients met the inclusion criteria. A total of 168 TP PBx were pair-matched to 336 TR PBx patients. Baseline demographics and imaging characteristics were similar between the groups. Per patient, the CSPCa detection was 2.1% vs 6.3% (p = 0.4) for PIRADS 1–2, and 59% vs 60% (p = 0.9) for PIRADS 3–5, on TP vs TR PBx, respectively. Per lesion, the CSPCa detection for PIRADS 3 (21% vs 16%; p = 0.4), PIRADS 4 (51% vs 44%; p = 0.8) and PIRADS 5 (76% vs 84%; p = 0.3) was similar for TP vs TR PBx, respectively. However, the TP PBx showed a longer maximum cancer core length (11 vs 9 mm; p = 0.02) and higher cancer core involvement (83% vs 65%; p < 0.001) than TR PBx. Independent predictors for CSPCa detection were age, PSA, PV, abnormal digital rectal examination findings, and PIRADS 3–5. Our study demonstrated transperineal MRI/TRUS fusion PBx provides similar CSPCa detection, with larger prostate cancer core length and percent of core involvement, than transrectal PBx.